Latest News.

AAN Mayo Clinic Travel Grant Winners

Congratulations to the three young researchers who are heading to the International Symposium of Amyloidosis at the Mayo Clinic on AAN travel grants Photo by Leslie Beasley on Unsplash The AAN Board is delighted to announce the award of travel grants of $5000 to three Young Australian researchers to attend the [...]

2024-04-09T19:48:01+10:00March 28th, 2024|AAN Community, Blog, Latest News.|

Mrs Patricia Neely – Member of the Order of Australia (AM)

Congratulations to our Pat Neely, newly appointed Member of the Order of Australia for her services for the amyloidosis community. The AAN proudly congratulates Pat Neely, a founding member and recently retired Board member the AAN who has been appointed a Member of the Order of Australia (AM). [...]

2024-02-02T10:16:36+11:00February 2nd, 2024|Latest News.|

PBAC recommends patisiran for ATTRv with neuropathy

Patisiran has been recommended by the Pharmaceutical Benefits Advisory Committee for those with hereditary transthyretin amyloidosis with polyneuropathy. Patisiran is an intravenous a gene silencing therapy that is given every 3 weeks. In the landmark APOLLO trial Patisiran was proven to reduce the production of the disease-causing transthryretin protein resulting [...]

2024-02-02T10:14:10+11:00February 2nd, 2024|Latest News.|

Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy

Abstract Background Transthyretin amyloid cardiomyopathy is characterized by the deposition of misfolded monomeric transthyretin (TTR) in the heart. Acoramidis is a high-affinity TTR stabilizer that acts to inhibit dissociation of tetrameric TTR and leads to more than 90% stabilization across the dosing interval as measured ex vivo. Conclusions [...]

2024-01-21T23:48:28+11:00January 21st, 2024|Latest News.|

Consensus recommendations on holistic care in hereditary ATTR amyloidosis

Hereditary transthyretin-mediated amyloidosis is a rare, progressive and potentially life- limiting multisystem disease, affecting every aspect of a patient’s life. This online international Delphi survey aimed to evolve clinical−patient-led practical guidance, to inspire and encourage a holistic approach to care that is managed in specialist settings by multidisciplinary teams [...]

2023-09-19T15:50:23+10:00September 19th, 2023|Blog, Latest News.|

Positive progress towards Medicare funded access to Tafamidis and Patisiran for ATTR

PBAC has recommended PBS listing of Vyndamax®(tafamidis) 61mg for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) with NYHA Class I-II heart failure.  The latest Pharmaceutical Benefits Advisory Committee (PBAC) Meeting was held in July and it recommended the Public Benefit Scheme (PBS) listing of Vyndamax (tafamidis) 61 mg for patients [...]

2023-08-21T11:59:42+10:00August 21st, 2023|Latest News.|

Coronavirus: Instructions for amyloidosis patients

Vaccination is vital to help control COVID-19 and keep you and the community well. If we in Australia with the rest of the world are going to control COVID-19 also known as the  Coronavirus  and we want the Australian state borders to remain open, it is extremely important [...]

2021-12-19T22:30:16+11:00December 19th, 2021|Latest News.|

Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy

Authors David Adams Yukio Ando João Melo Beirão Teresa Coelho Morie A. Gertz Julian D. Gillmore Philip N. Hawkins Isabelle Lousada Ole B. Suhr Giampaolo Merlini Abstract Amyloid transthyretin (ATTR) amyloidosis with polyneuropathy (PN) is a progressive, debilitating, systemic disease wherein transthyretin protein misfolds to form amyloid, which is deposited in the endoneurium. ATTR amyloidosis with PN is the most serious hereditary polyneuropathy [...]

2020-01-14T17:54:26+11:00January 14th, 2020|Latest News.|

2nd European meeting for ATTR amyloidosis

Reports from the 2nd European meeting for ATTR amyloidosis for doctors and patients from the NZ ATTR Amyloidosis Patients Association and the Australian ATTR Amyloidosis Alliance representative. This very successful fourday conference was held at the beginning of September in Berlin. Amongst the delegates were Jaime and Aubrey Christmas who [...]

2019-10-17T09:38:09+11:00October 17th, 2019|Latest News.|

2019 International Myeloma Workshop

The International Myeloma Workshop was held in Boston, USA from 12th-15th September 2019. This is a conference attended by >3000 medical professionals every 2 years, where world leaders in the treatment of myeloma and associated disease - such as systemic AL amyloidosis - present and discuss data regarding new [...]

2019-09-22T18:15:56+10:00September 22nd, 2019|Latest News.|
Go to Top